NASDAQ:MREO
Mereo Biopharma Group Plc Stock News
$3.45
-0.180 (-4.96%)
At Close: Jul 02, 2024
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announ
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
07:30am, Thursday, 30'th May 2024
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announc
Equities Analysts Offer Predictions for Mereo BioPharma Group plc’s Q2 2024 Earnings (NASDAQ:MREO)
01:38am, Monday, 20'th May 2024
Mereo BioPharma Group plc (NASDAQ:MREO – Free Report) – Equities researchers at Leerink Partnrs issued their Q2 2024 earnings per share estimates for shares of Mereo BioPharma Group in a r
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 15'th May 2024
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announc
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Friday, 12'th Apr 2024
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
07:30am, Wednesday, 03'rd Apr 2024
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today annou
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 27'th Mar 2024
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
05:34pm, Thursday, 14'th Mar 2024
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation th
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
07:30am, Tuesday, 05'th Mar 2024
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today annou
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
07:00am, Monday, 08'th Jan 2024
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
04:01pm, Monday, 23'rd Oct 2023
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provid
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
07:00am, Thursday, 21'st Sep 2023
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today annou
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
07:30am, Thursday, 07'th Sep 2023
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today annou
What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now?
01:43pm, Friday, 21'st Apr 2023
Does MEREO BIOPHARMA (MREO) have what it takes to be a top stock pick for momentum investors? Let's find out.
4 Hot Penny Stocks To Watch With News This Week
09:01am, Tuesday, 21'st Mar 2023
Penny stocks to watch this week. The post 4 Hot Penny Stocks To Watch With News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.